Climb Bio (CLYM) investor relations material

Lead program overviews and clinical progress

• Two lead assets, CLYM116 (APRIL monoclonal) and budoprutug (anti-CD19 monoclonal), target unmet needs in B-cell mediated diseases with large commercial potential.

• CLYM116 demonstrated best-in-class PK/PD and APRIL suppression in recent phase I data, supporting its potential in IgA nephropathy (IgAN).

• Budoprutug targets CD19, offering broader B-cell depletion than CD20 therapies and is being evaluated in MN, ITP, and SLE.

• Both programs have rich data calendars with multiple clinical readouts expected through this year and next.

• Parallel development in China accelerates global data generation and regulatory alignment for CLYM116.

CLYM116: Differentiation, dosing, and competitive positioning

• CLYM116 uses a sweeper mechanism to degrade APRIL, overcoming PK limitations of earlier agents and enabling Q12-week dosing.

• Q12-week auto-injector dosing is seen as a major advantage for patient adherence and lifestyle fit, especially for young, asymptomatic IgAN patients.

• NAVIGATE-2 phase II study is designed to confirm optimal dosing and APRIL suppression, with phase III planning underway in parallel.

• Safety profile is being closely monitored, with early data suggesting differentiation from BAFF-APRIL agents and lower risk of high molecular weight complexes.

• Competitive landscape is evolving, with guidelines favoring combination approaches and APRIL-only agents expected to be preferred due to efficacy and safety.

Budoprutug: Clinical rationale and development strategy

• CD19 targeting offers efficacy in patients where CD20 therapies have failed, with a favorable safety profile compared to CAR T or T-cell engagers.

• Early ITP data in heavily pretreated patients showed promising platelet responses, supporting further development and potential for earlier-line use.

• MN and ITP are prioritized for registrational studies due to high unmet need and manageable trial sizes for a small company.

• Subcutaneous administration is being explored to broaden patient appeal and provide flexible treatment options.